173 Medial Prefrontal Cortex Activity during the Extinction of Conditioned Fear: An Investigation Using Functional Near-Infrared Spectroscopy
Guhn, A. (Würzburg); Dresler, T. (Würzburg/Tübingen); Hahn, T. (Würzburg/Frankfurt); Mühlberger, A. (Würzburg); Ströhle, A. (Berlin); Deckert, J.; Herrmann, M.J. (Würzburg)

183 Increase in Serum Brain-Derived Neurotrophic Factor in Met Allele Carriers of the BDNF Val66Met Polymorphism Is Specific to Males
Bus, R.A.A.; Arias-Vasquez, A.; Frankle, B. (Nijmegen); Prickaerts, J. (Maastricht); de Graaf, J. (Nijmegen); Voshaar, R.C.O. (Nijmegen/Groningen)

188 EEG Vigilance Regulation Patterns and Their Discriminative Power to Separate Patients with Major Depression from Healthy Controls

195 Neuropeptide-S Evoked Arousal with Electroencephalogram Slow-Wave Compensatory Drive in Rats
Ahnaou, A.; Drinkenburg, W.H.I.M. (Beerse)

206 Cognitive Impairment and Formal Thought Disorders in Parents of Early-Onset Schizophrenia Patients
Remberk, B.; Namysłowska, I.; Rybakowski, F. (Warsaw)

216 Influence of Antipsychotic Agents on Heart Rate Variability in Male WKY Rats: Implications for Cardiovascular Safety
Wang, Y.-C. (Hualien); Chen, C.-Y.; Kuo, T.B.J. (Taipei); Lai, C.-J. (Hualien); Yang, C.C.H. (Taipei)

227 Low-Frequency rTMS over Right Dorsolateral Prefrontal Cortex in the Treatment of Resistant Depression: Cognitive Improvement Is Independent from Clinical Response, Resting Motor Threshold Is Related to Clinical Response
Pallanti, S. (New York, N.Y./Florence); Di Rollo, A.; Antonini, S. (Florence); Causali, G. (Milan); Hollander, E. (New York, N.Y.); Quercioli, L. (Florence)

236 Erratum

236 Contents Vol. 65, 2012
Adverse Cutaneous Drug Eruptions

Editor Lars E. French

The skin is one of the most frequently involved organs in adverse drug reactions. Occurring with an incidence of 1–5% for certain types of drugs, cutaneous drug eruptions are mostly benign in nature, and comprise the most common type of eruption and urticaria. However, about one third of them require hospital treatment, leading to a considerable burden for the health care system.

In this book, a selected group of experts provide an up-to-date, condensed and clinically relevant overview of the field of cutaneous drug eruptions, ranging from epidemiology and genetic predisposition to available therapeutic measures, including rapid drug desensitization. Reflecting the great progress made in recent years in this field, this publication will be a useful tool for a better understanding diagnosis and management of cutaneous drug eruptions, not only for general physicians, dermatologists and clinical allergologists, but also for nurses and scientists.

Contents
Preface: French, L.E.
Epidemiology of Adverse Drug Reactions: Mackenauer, M.
Genetics and the Potential for Predictive Tests in Adverse Drug Reactions: Pirmohamed, M.
Toxicological and Pathogenesis of Adverse Drug Reactions: Neumann, O.; Schneider, B.; Pichler, M.W.
Diagnostic Approach to Drug Allergy: Har, T.
Histopathological Patterns Indicative of Distinct Adverse Drug Reactions: Kell, K.
Uncomplicated Drug-Induced Disseminated Exanthemas: Bircher, A.J.
Drug-Induced Angioedema: Leroi, M.
Fixed Drug Eruption: The Dark Side of Activation of Intraepidermal CD8+ T Cells: Uniquely Specialized to Mediate Protective Immunity: Shoshana, T.; Miszewski, Y.
Drug-Induced Hypersensitivity Syndrome: Recent Advances in the Diagnosis, Pathogenesis and Management: Shoshana, T.; Ramos, T.; Takahashi, R.; Ihla, T.; Mizewski, Y.

Acute Generalized Exanthematous Pustulosis: Jolelow-A.
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Har, T.; French, L.E.
Immediate and Delayed Cutaneous Reactions to Radiocontrast Media: Breuere, K.
Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs: Bosset, F.; Schwenk, M.; Rozen, Z.
Cutaneous Drug Eruptions Associated with the Use of Biologicals and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases: Semmelweis, A.; Milpied, R.; Teich, A.
Desensitization for Hypersensitivity Reactions to Medications: del Carmen Sanchon, M.; Breuere, K.; Olems, O.; Castelli, M.

Author Index

Delocalized Drug Eruptions: Describes the difference between localized drug eruptions and those that cover a larger area of the skin. It discusses the factors that contribute to the development of these reactions, including the pharmacokinetics of the drug, the individual's genetic makeup, and the presence of preexisting skin conditions.

Immediate and Delayed Cutaneous Reactions: Discusses the differences between these two types of reactions, as well as the mechanisms involved in each. Immediate reactions are mediated by immunoglobulin E (IgE) antibodies, while delayed reactions are mediated by other immune cells.

Fixed Drug Eruption: Explains the characteristics of this type of reaction, including the location, shape, and duration of the eruption. It also discusses the factors that contribute to the development of this condition.

Drug-Induced Angioedema: Provides an overview of the causes, symptoms, and treatment options for this condition. It also discusses the potential long-term effects of angioedema.

Fixed Drug Eruption: The Dark Side of Activation of Intraepidermal CD8+ T Cells: Discusses the role of these cells in the development of fixed drug eruptions. It also explores the potential implications of these findings for the development of new therapies for this condition.

Drug-Induced Hypersensitivity Syndrome: Recent Advances in the Diagnosis, Pathogenesis and Management: Provides an overview of the latest advances in the diagnosis and management of drug-induced hypersensitivity syndromes. It also discusses the potential implications of these findings for future research.

Acute Generalized Exanthematous Pustulosis: Discusses the causes, symptoms, and treatment options for this condition. It also explores the potential long-term effects of this reaction.

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Provides an overview of the causes, symptoms, and treatment options for these conditions. It also discusses the potential long-term effects of these reactions.

Phototoxic and Photoallergic Cutaneous Drug Reactions: Discusses the causes, symptoms, and treatment options for these conditions. It also explores the potential implications of these findings for future research.

Immediate and Delayed Cutaneous Reactions to Radiocontrast Media: Provides an overview of the causes, symptoms, and treatment options for these reactions. It also discusses the potential long-term effects of these reactions.

Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs: Discusses the causes, symptoms, and treatment options for these reactions. It also explores the potential implications of these findings for future research.

Cutaneous Drug Eruptions Associated with the Use of Biologicals and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases: Provides an overview of the causes, symptoms, and treatment options for these conditions. It also discusses the potential long-term effects of these reactions.

Desensitization for Hypersensitivity Reactions to Medications: Discusses the causes, symptoms, and treatment options for these reactions. It also explores the potential implications of these findings for future research.

Despite the availability of antidepressants for over 40 years, a substantial proportion of depressed patients do not respond adequately to treatment. Failure to respond effectively to treatment contributes to physical ill-health and psychiatric morbidity, often resulting in premature death of the depressed patient. The purpose of this volume is to discuss the possible reasons for the limitations of the currently available antidepressants, to examine the advances in our understanding of the psychopharmacology of depression and how such knowledge may assist in the discovery of new methods of treatment. Leading international experts in this field discuss the possible under- lying reasons for depression and limitations of current antidepressants. Opportunities for novel therapeutic approaches to dysfunction al circadian rhythms and mood disorders as well as current status and future perspectives for optimizing antidepressant management of depression are reviewed.

This publication illustrates the breadth of the latest research and valuable reading for psychiatrists, neuroscientists and pharmacologists.

Preface
What’s new in antidepressant research?

Experimental Models of Depression and the Mechanisms of Action of Antidepressants
Animal Models of Depression – Where Are We Going? Brinton, D.A.; Cryan, J.F.
Genetic Models of Depression and Antidepressant Responses: Kerkow, E.
Chromatin-Based Treatments for Affective Disorders – Insight or Utopia? Cerganov, H.Z.; Bertoni, O.
Neurotrophic Factors and Antidepressant Action: Recent Advances: Leyp, O.P.; Castren, E.
Neurogenic Basis of Antidepressant Action: Recent Advances: Tenti, A.; Belzung, C.

Optimizing Antidepressant Management of Depression: Current Status and Future Perspectives: Schwartz, T.L.; Stahl, S.M.

Experimental Models of Depression and the Mechanisms of Action of Antidepressants

Animal Models of Depression – Where Are We Going?

Brinton, D.A.; Cryan, J.F.

Genetic Models of Depression and Antidepressant Responses:

Kerkow, E.

The Role of 5-HT3 Receptors in the Antidepressant Response:

A Critical Review: Martin, C.P.; Hennen, M.; Lenflemp, L.; Monges, R.

Chromatin-Based Treatments for Affective Disorders – Insight or Utopia?

Cerganov, H.Z.; Bertoni, O.

Neurotrophic Factors and Antidepressant Action:

Recent Advances: Leyp, O.P.; Castren, E.

Neurogenic Basis of Antidepressant Action:

Recent Advances: Tenti, A.; Belzung, C.

The Future of Antidepressants:

The Nature and Treatment of Depression – Resistant Depression: Kennedy, S.H.; Rizvi, S.J.; Giacobbe, P.

Optimizing Antidepressant Management of Depression: Current Status and Future Perspectives: Schwartz, T.L.; Stahl, S.M.

What’s new in antidepressant research?
Guidelines for Authors

Submission
Only papers written in English are considered and should be submitted using the online submission website at: www.karger.com/nps. Should you experience any problems with your submission, please contact
Prof. W. Strik
University Hospital of Psychiatry Waldau
CH–3000 Bern 60 (Switzerland)
E-Mail: neuropsychobiology@puk.unibe.ch

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of ‘Neuropsychobiology’ and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Arrangement
Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as a running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: For indexing purposes, a list of 3–10 key words in English is essential.

Abstract: For each manuscript, a short title and a concise abstract of not more than 250 words in English is essential.

Key words: For indexing purposes, a list of 3–10 key words in English is essential.

References
In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2003; DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formating of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author's Choice
Karger's Author's Choice<sup>®</sup> service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice<sup>®</sup> service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/FAQ.htm#1

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger’s Author's Choice<sup>®</sup> feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges
There are no page charges for papers of 5 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 15 manuscript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the first-named author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

References
In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2003; DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice
Karger’s Author’s Choice<sup>®</sup> service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice<sup>®</sup> service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/FAQ.htm#1

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice<sup>®</sup> feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges
There are no page charges for papers of 5 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 15 manuscript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the first-named author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
The Asia-Pacific Experience with Dementia and Cognitive Disorders

Dementia: The Asia-Pacific Perspectives

Editor
Tze-Pin Ng

Contents

Introductions
Harnessing the Energy of the Asia Pacific: Chan-Palay, V.
The Unparalleled Challenge of Aging Populations: Ng, T.-P.

Original Research Articles
Apolipoprotein E Polymorphism and Dementia: A Hospital-Based Study from Southern India: Bharath, S.; Purushottam, M.; Mukherjee, O.; Bageolly, B.S.; Prakash, O.; Kota, L.; Krishnappa, S.B.; Sivakumar, P.T.; Jain, S.; Varghese, M.

IL-6–174 G/C and ApoE Gene Polymorphisms in Alzheimer’s and Vascular Dementia Patients Attending the Cognitive Disorder Clinic of the All India Institute of Medical Sciences, New Delhi: Mansoori, N.; Tripathi, M.; Alam, R.; Luthra, R.; Parveen, S.; Mukhopadhyay, A.K.

Family Caregiving in Dementia: The Asian Perspective of a Global Problem: Chan, S.W.-C.

The Association of Metabolic Syndrome with Subclinical Ischemic Brain Lesions in Japanese Adults: Bokura, H.; Nagai, A.; Opuro, H.; Kobayashi, S.; Yamaguchi, S.

Apolipoprotein E Polymorphism and Age at Onset of Alzheimer’s Disease in a Quadratic Sample: Kwon, O.D.; Khaleeq, A.; Chan, W.; Pavlik, V.K.; Doody, R.S.

Interethnic Differences in Dementia Epidemiology: Global and Asia-Pacific Perspectives: Venketasubramanian, N.; Sahadevan, S.; Kuo, E.H.; Chen, C.P.L.; Ng, T.-P.

Recognition, Attitudes and Causal Beliefs regarding Dementia in Italian, Greek and Chinese Australians: Low, L.-F.; Anstey, K.J.; Lackensteen, S.M.; Camit, M.; Harrison, F.; Draper, B.; Brodaty, H.

Why Family Caregivers Choose to Institutionalize a Loved One with Dementia: A Singapore Perspective: Tew, C.W.; Tan, L.F.; Luo, N.; Ng, W.Y.; Yap, P.

Association between Body Mass Index and Cognitive Function among Chinese Nonagenarians/Centenarians: Chong, M.S.; Lim, W.S.; Chan, S.P.; Feng, L.; Niti, M.; Yap, P.; Yeo, D.; Ng, T.-P.

Sociodemographic Risk Factors and Correlates of Dementia in Older Malaysians: Hamid, T.A.; Krishnaswamy, S.; Abdullah, S.S.; Montaz, Y.A.

A Controlled Naturalistic Study on a Weekly Music Therapy and Activity Program on Disruptive and Depressive Behaviors in Dementia: Han, P.; Kwan, M.; Chen, D.; Yusoff, S.Z.; Chionh, H.L.; Goh, J.; Yap, P.


www.karger.com/dem
Contents

See the journal website for contents
Effects of Traumatic Stress
Molecular and Hormonal Mechanisms

September 11-14, 2012
New York, NY

http://ispne.org
Conference ‘NeuroCultures – NeuroGenderings II’

From 13 to 15 September 2012 at the University of Vienna

Organizers

In co-operation with the network Neurogenderings, the Gender Studies Chair/Prof. Sigrid Schmitz and the Gender Research Office of the University of Vienna/Austria launch the three-day international, interdisciplinary conference NeuroCultures – NeuroGenderings II.

Aim of the conference

The aim of the conference is to improve reflective scientific approaches concerned with sex/gender and the brain, and to gain particular insight into the transformation or persistence of gendered norms and values that accompany the mutual entanglements between brain research, various disciplines and public discourse.

Therefore scientists and emerging scholars are invited, who work on issues within the neurosciences/neurocultures and/or those whose work is situated within the social sciences/cultural studies, medical or science technology studies, as well as those working on relevant projects from a feminist and queer perspective.

Keynote-Speakers

• Prof. Hilary Rose (Professor Emeritus of Social Policy at the University of Bradford and Professor Emeritus of Physics, Gresham College, London, UK)
• Prof. Daphna Joel (Head of the Psychobiology Graduate Program at the Department of Psychology, Tel Aviv University, Israel)

Sessions and Poster Presentations

The conference sessions will focus on the following thematic strands: Empirical NeuroGenderings, NeuroCultures and Brain Plasticity, Image and Politics of the Cerebral Subject, Power and Politics of NeuroCultures/NeuroGenderings, Transdisciplinary and NeuroGenderings, Theory and Epistemology of NeuroGenderings and other gender relevant fields of research. In particular, young researchers will be included by poster presentations.

The network Neurogenderings aims to provide a presentation platform for sharing recent developments within the field of neurocultures and gender with the scientific community and the public, for discussing research results and for developing new interdisciplinary research cooperations.

More Information about the conference is available at: http://neurocultures2012.univie.ac.at/
E-Mail: neurocultures2012.gender@univie.ac.at

universität Wien
2nd International Congress on Borderline Personality Disorder and Allied Disorders
Matching research, need and demand to treatment and resources

27 – 29 September 2012
Amsterdam RAI Convention Centre
THE NETHERLANDS

3RD ANNOUNCEMENT

16th WORLD CONGRESS OF PSYCHOPHYSIOLOGY
SEPTEMBER 13-17 PISA, ITALY
Official World Congress of the International Organization of Psychophysiology (IOP)

DEADLINE FOR ABSTRACT SUBMISSION:
APRIL 25, 2012

MAIN TOPICS
Psychophysiology of Cognitive and Memory Disorders
Psychophysiology of Learning Disabilities and ADHD
Clinical Developmental Psychophysiology
Cardiovascular Psychophysiology
Psychophysiology of Emotion
Psychopharmacoeeg

World Congress Website: www.iop2012.it
Official IOP Website: www.iopworld.org
E-mail for general queries: info@iop2012.it

INVITED SPEAKERS
Lamberto Maffei, Pisa, ITALY
Andrew Papanicolau, Tennessee, USA
Leslie Prichep, New York, USA
Giacomo Rizzolatti, Parma, ITALY
Paolo Maria Rossini, Rome, ITALY
Wolf Singer, Berlin, GERMANY

IOP President
Prof. Giuseppe Chiarenza
president@iopworld.org

President, 16th World Congress of IOP
Prof. Pietro Pietrini
pietro.pietrini@med.unipi.it

Scientific Coordinator of Abstracts
Dott. Emiliano Ricciardi
abstract@iop2012.it

Chairman, Local Scientific Committee
16th World Congress of IOP
Prof. Mario Guazzelli
m.guazzelli@psico.med.unipi.it
Alzheimer’s and Parkinson’s Diseases: Advances, Concepts and New Challenges
Proceedings

Editors
Roger M. Nitsch
Abraham Fisher
Manfred Windisch
Israel Hanin

Selected Contents

Software Tool for Improved Prediction of Alzheimer’s Disease: Soininen, H. et al.

Immunization and Innate Immunity
Innate Immunity and the Etiology of Late-Onset Alzheimer’s Disease: Eikelenboom, P. et al.
Curcumin Promotes Monocytic Gene Expression Related to β-Amyloid and Superoxide Dismutase Clearance: Cashman, J.R. et al.

Prion Proteins, Statins, Cholesterol
α-Secretase-Derived Cleavage of Cellular Prion Protein Yields Biologically Active Catabolites with Distinct Functions: Guillot-Sestier, M.-V.; Checler, F.
Cellular Prion Protein Mediates Toxic Signaling of Amyloid Beta: Resenberger, U.K.; Winkhofer, K.F.; Tatutzl, J.
Dual Effects of Statins on Aβ Metabolism: Upregulation of the Degradation of APP-CTF and Aβ Cleavage: Sato, N. et al.

Cerebrovascular Lesions and Primary Neurodegenerative Diseases
Insights into Caspase-Mediated Apoptotic Pathways Induced by Amyloid-β in Cerebral Microvascular Endothelial Cells: Fossati, S. et al.
Neuroinflammation and Blood-Brain Barrier Changes in Capillary Amyloid Angiopathy: Carrano, A. et al.

For full table of contents please log on to www.karger.com/ndd
Adverse Cutaneous Drug Eruptions

Editor Lars E. French

The skin is one of the most frequently involved organs in adverse drug reactions. Occurring with an incidence of 1–5% for certain types of drugs, cutaneous drug eruptions are mostly benign in nature, and comprise the mainly popular type of eruption and urticaria. However, about one-third of them require hospital treatment, leading to a considerable burden for the health care system.

In this book, a selected group of experts provide an up-to-date, condensed and clinically relevant overview of the field of cutaneous drug eruptions, ranging from epidemiology and genetic predisposition to available therapeutic measures, including rapid drug desensitization. Reflecting the great progress made in recent years in this field, this publication will be a useful tool for a better understanding of diagnosis and management of cutaneous drug eruptions, not only for general physicians, dermatologists and clinical allergologists, but also for nurses and scientists.

Contents
Preface: French, L.E.
Epidemiology of Adverse Drug Reactions: Mochonhaup, M.
Genetics and the Potential for Predictive Tests in Adverse Drug Reactions: Pirmahomed, M.
Pharmacology and Pathogenesis of Adverse Drug Reactions: Neumann, O.; Schneele, B.; Pichler, M.J.
Diagnostic Approach to Drug Allergy: Harz, T.
Histopathological Patterns and Indicators of Distinct Adverse Drug Reactions: Karl, K.
Uncomplicated Drug Induced Disseminated Exanthemata: Bircher, A.J.
Drug Induced Angioedema: Lenz, M.
Fixed Drug Eruption: The Dark Side of Activation of Intraepidermal CD8+ T Cells: Uniquely Specialized to Mediate Protective Immunity: Shiohara, T.; Mizukawa, Y.
Acute Generalized Exanthematous Pustulosis: Joder, A.
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Mercier, T.; French, L.E.
Phototoxic and Photoallergic Cutaneous Drug Reactions: Glini, M.; Holthausen, G.J.
Immediate and Delayed Cutaneous Reactions to Radiocontrast Media: Broekhove, K.
Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs: Brestovski, B.; Zichov, R.; Goldhirsch, S.M.; Drummer, S.
Cutaneous Drug Eruptions Associated with the Use of Biologics and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases: Samuels, J.J.; Milpied, R.; Tezak, A.
Deensensitization for Hypersensitivity Reactions to Medications: del Carmen Sancho, M.; Brestovski, R.; Olsme, O.; Castelli, M.

Author Index
Subject Index

Despite the availability of antidepressants for over 40 years, a substantial proportion of depressed patients do not respond adequately to treatment. Failure to respond effectively to treatment contributes to physical illness and psychopathological morbidity, often resulting in premature death of the depressed patient. The purpose of this volume is to consider the possible reasons for the limitations of the currently available antidepressants, to examine the advances in our understanding of the psychopharmacology of depression, and how such knowledge may assist in the discovery of new methods of treatment.

Leading international experts in this field discuss the possible underlying reasons for depression and limitations of current antidepressants. Opportunities for novel therapeutic approaches to dysfunction in neurotransmitter pathways and mood disorders as well as current status and future perspectives for optimizing antidepressant management of depression are reviewed.

This publication illustrates the breadth of the latest research and valuable reading for psychiatrists, neuroscientists and pharmacologists.

Contents
Basic and Clinical Aspects of Depression Research: The Hypothalamic-Pituitary-Adrenal Axis in Depression: Van der Put, M.; Simon, T.G.
Neuroendocrine Rhythms and Mood Disorders: Opportunities for Novel Therapeutic Approaches: Norman, T.R.
The Concept of Depression as a Dysfunction of the Immune System: Leonardi, B.E.
The Role of Polysaturated Fatty Acids in the Pathology and Treatment of Depression: Sagg, C.
Antidepressant Treatment Resistance: Focus on Glutamate: Mammaglio, J.R.; Mathes, S.J.
Neuromodulation and the Pathophysiology and Treatment of Depression: Recent Advances and Future Needs: Canon, D.

Editor(s): J.F. Cryan

Experimental Models of Depression and the Mechanisms of Action of Antidepressants
Animal Models of Depression – Where Are We Going?: Binette, D.A.; Cryan, J.F.
Genetic Models of Depression and Antidepressant Response: Leonardi, B.E.
Chromatin-Based Treatments for Affective Disorders – Insight or Utopia: Constantin, M.F.; (B) Berrett, O.
Neurotrophic Factors and Antidepressant Action: Recent Advances: de Leep, O.; Castron, E.
Neurogenic Basis of Antidepressant Action: Recent Advances: Tanti, A.; Delargy, C.
The Future of Antidepressants
The Nature and Treatment of Therapy-Resistant Depression: Anthony, D.J.; Rave, S.J.; Giacobbe, P.
Optimizing Antidepressant Management of Depression: Current Status and Future Perspectives: Schwartz, T.L.; Stahl, S.M.

Please send: ______ copies
Postage and handling free with prepayment

Payment: Please charge my credit card

American Express
Diners Club
Eurocard
Mastercard
Visa

Order may be placed with any bookstore, subscription agency, directly with the publisher or through a Karger distributor.

E-Mail orders@karger.ch

www.karger.ch/chial

KARGER

Chemical Immunology and Allergy, Vol. 97
Series Editors: Ring, J. (Munich); Bienen, K. (Duisberg)
Capron, M. (Moulins); Bircher, A-J. (Bern); Holgate, S.T. (Southampton); Meriën, G. (Nantes); Sato, H. (Tokyo)
VIII + 272 p., 11 fig., 13 tab., hard cover, 2010
Price subject to change
CHF 160.– / EUR 140.– / USD 200.00
Postage and handling free with prepayment

Depression: From Psychopathology to Pharmacotherapy
Editors: John F. Cryan
Brian E. Leonard

Preface
Antidepressants: Past and Present
Antidepressant Compounds: A Critical Review
Basic and Clinical Aspects of Depression Research
The Hypothalamic-Pituitary-Adrenal Axis in Depression
Neuroendocrine Rhythms and Mood Disorders: Opportunities for Novel Therapeutic Approaches: Norman, T.R.
The Concept of Depression as a Dysfunction of the Immune System: Leonardi, B.E.
The Role of Polysaturated Fatty Acids in the Pathology and Treatment of Depression: Sagg, C.
Antidepressant Treatment Resistance: Focus on Glutamate: Mammaglio, J.R.; Mathes, S.J.
Neuromodulation and the Pathophysiology and Treatment of Depression: Recent Advances and Future Needs: Canon, D.

Please send: ______ copies
Postage and handling free with prepayment

Payment: Please charge my credit card

American Express
Diners Club
Eurocard
Mastercard
Visa

Order may be placed with any bookstore, subscription agency, directly with the publisher or through a Karger distributor.

E-Mail orders@karger.ch

www.karger.com/mophth

KARGER

Modern Trends in Psychopharmacology, Vol. 27
Editors: Leonard, B.J.; Gallo, A.
VIII + 308 p., 28 fig., 20 tab., hard cover, 2011
Price subject to change
CHF 180.– / EUR 160.– / USD 240.00
Postage and handling free with prepayment

www.karger.com
Original Papers

173 Medial Prefrontal Cortex Activity during the Extinction of Conditioned Fear: An Investigation Using Functional Near-Infrared Spectroscopy
Guhn, A. (Würzburg); Dresler, T. (Würzburg/Tübingen); Hahn, T. (Würzburg/Frankfurt); Mühlberger, A. (Würzburg); Ströhle, A. (Berlin); Deckert, J.; Herrmann, M.J. (Würzburg)

183 Increase in Serum Brain-Derived Neurotrophic Factor in Met Allele Carriers of the BDNF Val66Met Polymorphism Is Specific to Males
Bus, B.A.A.; Arias-Vasquez, A.; Frankle, B.; (Nijmegen); Prickaerts, J. (Maastricht); de Graaf, J. (Nijmegen); Voshaar, R.C.O. (Nijmegen/Groningen)

188 EEG Vigilance Regulation Patterns and Their Discriminative Power to Separate Patients with Major Depression from Healthy Controls

195 Neuropeptide-S Evoked Arousal with Electroencephalogram Slow-Wave Compensatory Drive in Rats
Ahnaou, A.; Drinkenburg, W.H.I.M. (Beerse)

206 Cognitive Impairment and Formal Thought Disorders in Parents of Early-Onset Schizophrenia Patients
Remberk, B.; Namysłowska, I.; Bybakowski, F. (Warsaw)

216 Influence of Antipsychotic Agents on Heart Rate Variability in Male WKY Rats: Implications for Cardiovascular Safety
Wang, Y.-C. (Hualien); Chen, C.-Y.; Kuo, T.B.J. (Taipei); Lai, C.-J. (Hualien); Yang, C.C.H. (Taipei)

227 Low-Frequency rTMS over Right Dorsolateral Prefrontal Cortex in the Treatment of Resistant Depression: Cognitive Improvement Is Independent from Clinical Response, Resting Motor Threshold Is Related to Clinical Response
Pallanti, S. (New York, N.Y./Florence); Di Rollo, A.; Antonini, S. (Florence); Casali, G. (Milan); Holland, E. (New York, N.Y.); Quercioli, L. (Florence)

236 Erratum

236 Contents Vol. 65, 2012